Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
OPEN The Korean journal of internal medicine | 28 Nov 2017
SM Jung, SK Kwok, JH Ju, YB Park and SH Park
Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insurance claims data.
* Data courtesy of Altmetric.com